-+ 0.00%
-+ 0.00%
-+ 0.00%

BioMarin Pharmaceutical Plans To Discontinue Dosing, Enrollment In Its Phase 2 Studies For VOXZOGO In Turner Syndrome

Benzinga·03/16/2026 12:54:31
Listen to the news

SEC.